Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Two-year effects of semaglutide in adults with overweight or obesity: the STEP 5 trial
W. Timothy Garvey, Rachel L. Batterham, Meena Bhatta, et al.
Nature Medicine (2022) Vol. 28, Iss. 10, pp. 2083-2091
Open Access | Times Cited: 396

Showing 26-50 of 396 citing articles:

Targeting the incretin system in obesity and type 2 diabetes mellitus
Saleem Ansari, Bernard Khoo, Tricia Tan
Nature Reviews Endocrinology (2024) Vol. 20, Iss. 8, pp. 447-459
Closed Access | Times Cited: 29
Semaglutide vs Endoscopic Sleeve Gastroplasty for Weight Loss
Muhammad Haseeb, Jagpreet Chhatwal, Jade Xiao, et al.
JAMA Network Open (2024) Vol. 7, Iss. 4, pp. e246221-e246221
Open Access | Times Cited: 25
Transforming obesity: The advancement of multi-receptor drugs
Christine M. Kusminski, Diego Pérez–Tilve, Timo D. Müller, et al.
Cell (2024) Vol. 187, Iss. 15, pp. 3829-3853
Closed Access | Times Cited: 22
Efficacy and safety of once-weekly semaglutide 2·4 mg versus placebo in people with obesity and prediabetes (STEP 10): a randomised, double-blind, placebo-controlled, multicentre phase 3 trial
Barbara McGowan, Jens Meldgaard Bruun, Matt Capehorn, et al.
The Lancet Diabetes & Endocrinology (2024) Vol. 12, Iss. 9, pp. 631-642
Closed Access | Times Cited: 21
Prevention of cardiorenal complications in people with type 2 diabetes and obesity
Daniel J. Drucker
Cell Metabolism (2024) Vol. 36, Iss. 2, pp. 338-353
Open Access | Times Cited: 19
GLP-1 agonists: A review for emergency clinicians
Brit Long, Jessica Pelletier, Alex Koyfman, et al.
The American Journal of Emergency Medicine (2024) Vol. 78, pp. 89-94
Closed Access | Times Cited: 19
Recent Advances in Endometrial Cancer Prevention, Early Diagnosis and Treatment
Holly Baker‐Rand, Sarah Kitson
Cancers (2024) Vol. 16, Iss. 5, pp. 1028-1028
Open Access | Times Cited: 19
Review article: Pharmacologic management of obesity ‐ updates on approved medications, indications and risks
Camille Lupiañez-Merly, Saam Dilmaghani, Kia Vosoughi, et al.
Alimentary Pharmacology & Therapeutics (2024) Vol. 59, Iss. 4, pp. 475-491
Closed Access | Times Cited: 18
Pharmacotherapy for obesity: moving towards efficacy improvement
Walmir Coutinho, Bruno Halpern
Diabetology & Metabolic Syndrome (2024) Vol. 16, Iss. 1
Open Access | Times Cited: 18
Bone Health After Exercise Alone, GLP-1 Receptor Agonist Treatment, or Combination Treatment
Simon Birk Kjær Jensen, Victor Sørensen, Rasmus Michael Sandsdal, et al.
JAMA Network Open (2024) Vol. 7, Iss. 6, pp. e2416775-e2416775
Open Access | Times Cited: 18
The Effect of Semaglutide on Mortality and COVID-19–Related Deaths
Benjamin M. Scirica, A. Michael Lincoff, Ildiko Lingvay, et al.
Journal of the American College of Cardiology (2024) Vol. 84, Iss. 17, pp. 1632-1642
Open Access | Times Cited: 18
Psychiatric Safety of Semaglutide for Weight Management in People Without Known Major Psychopathology
Thomas A. Wadden, Gregory K. Brown, Christina Egebjerg, et al.
JAMA Internal Medicine (2024)
Open Access | Times Cited: 17
Sex- and Gender-Related Differences in Obesity: From Pathophysiological Mechanisms to Clinical Implications
Andrijana Koceva, Rok Herman, Andrej Janež, et al.
International Journal of Molecular Sciences (2024) Vol. 25, Iss. 13, pp. 7342-7342
Open Access | Times Cited: 16
Obesity and cardiovascular disease: an ESC clinical consensus statement
Konstantinos C. Koskinas, Emeline M. Van Craenenbroeck, Charalambos Antoniades, et al.
European Journal of Preventive Cardiology (2024)
Open Access | Times Cited: 16
Once-weekly semaglutide versus placebo in adults with increased fracture risk: a randomised, double-blinded, two-centre, phase 2 trial
Morten Steen Hansen, Eva M. Wölfel, Shakespeare Jeromdesella, et al.
EClinicalMedicine (2024) Vol. 72, pp. 102624-102624
Open Access | Times Cited: 15
Integrated Management of Cardiovascular–Renal–Hepatic–Metabolic Syndrome: Expanding Roles of SGLT2is, GLP-1RAs, and GIP/GLP-1-RAs
Nikolaos Theodorakis, Maria Nikolaou
Biomedicines (2025) Vol. 13, Iss. 1, pp. 135-135
Open Access | Times Cited: 6
Efficacy and Safety of Glucagon-Like Peptide-1 Receptor Agonists for Weight Loss Among Adults Without Diabetes
Areesha Moiz, Kristian B. Filion, Helia Toutounchi, et al.
Annals of Internal Medicine (2025) Vol. 178, Iss. 2, pp. 199-217
Closed Access | Times Cited: 5
How ‘miracle’ weight‐loss semaglutide promises to change medicine but can we afford the expense?
Ralf Weiskirchen, Amedeo Lonardo
British Journal of Pharmacology (2025)
Open Access | Times Cited: 3
Proteomic changes upon treatment with semaglutide in individuals with obesity
Lasse Maretty, Dipender Gill, Lotte Simonsen, et al.
Nature Medicine (2025)
Open Access | Times Cited: 2
GLP-1 and the Neurobiology of Eating Control: Recent Advances
Lauren A. Jones, Daniel I. Brierley
Endocrinology (2025)
Open Access | Times Cited: 2
Glucose-dependent insulinotropic polypeptide (GIP)
Timo D. Müller, Alice E. Adriaenssens, Bo Ahrén, et al.
Molecular Metabolism (2025) Vol. 95, pp. 102118-102118
Open Access | Times Cited: 2
A narrative review of approved and emerging anti-obesity medications
Semira Abdi Beshir, Asim Ahmed Elnour, Aadith Soorya, et al.
Saudi Pharmaceutical Journal (2023) Vol. 31, Iss. 10, pp. 101757-101757
Open Access | Times Cited: 36
Semaglutide and cancer: A systematic review and meta-analysis
Lakshmi Nagendra, BG Harish, Meha Sharma, et al.
Diabetes & Metabolic Syndrome Clinical Research & Reviews (2023) Vol. 17, Iss. 9, pp. 102834-102834
Closed Access | Times Cited: 34
A Comprehensive Review on Weight Loss Associated with Anti-Diabetic Medications
Fatma Haddad, Ghadeer Dokmak, Maryam Bader, et al.
Life (2023) Vol. 13, Iss. 4, pp. 1012-1012
Open Access | Times Cited: 33
Antipsychotic-Induced Weight Gain in Severe Mental Illness: Risk Factors and Special Considerations
Nicolette Stogios, Bailey Humber, Sri Mahavir Agarwal, et al.
Current Psychiatry Reports (2023) Vol. 25, Iss. 11, pp. 707-721
Closed Access | Times Cited: 32

Scroll to top